<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902926</url>
  </required_header>
  <id_info>
    <org_study_id>20160805</org_study_id>
    <nct_id>NCT02902926</nct_id>
  </id_info>
  <brief_title>Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients</brief_title>
  <official_title>Comparison of Microbiota and Quality of Life for a Low FODMAPs Versus Standard Dietary Advice in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinsong Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBS is a global disease, patients often because of long-term symptoms of recurrent, not
      timely diagnosis and treatment effect is not ideal and frequent treatment, seriously affect
      the quality of life, and cause the corresponding economic and social burden.At present，a
      number of studies suggest that fermentable oligosaccharides, disaccharides and
      monosaccharides and polyols (FODMAPs) can induce IBS symptoms.Data from large randomized
      controlled trials are limited, leaving clinicians with the challenge of providing patients
      with reliable guidance based on minimal evidence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBS is a global disease, patients often because of long-term symptoms of recurrent, not
      timely diagnosis and treatment effect is not ideal and frequent treatment, seriously affect
      the quality of life, and cause the corresponding economic and social burden.At present，a
      number of studies suggest that fermentable oligosaccharides, disaccharides and
      monosaccharides and polyols (FODMAPs) can induce IBS symptoms.Data from large randomized
      controlled trials are limited, leaving clinicians with the challenge of providing patients
      with reliable guidance based on minimal evidence.

      This study will compare the effect of low FODMAPs diet and usual diet instruction on
      Intestinal flora, intestinal short chain fatty acids and quality of life by two groups.The
      results will answer the effect and long-term safety of Low FODMAPs diet.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota / Short chain fatty acids</measure>
    <time_frame>Change from baseline Microbiota / Short chain fatty acids at 4 weeks</time_frame>
    <description>The fecal samples of IBS patients were analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Irritable bowel syndrome severity scoring system scale</measure>
    <time_frame>Baseline,1,and 3 month post randomization</time_frame>
    <description>Irritable bowel syndrome severity scoring system scale is an integral system for monitoring the severity of IBS in patients with disease severity.The scale is mainly from the degree of abdominal pain, abdominal pain frequency, abdominal distension, defecation satisfaction and the impact of life, according to the 10cm visual scoring method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Short Form 36 (SF-36) scale</measure>
    <time_frame>Baseline,1,and 3 month post randomization</time_frame>
    <description>SF-36 is a general scale, at present, the most commonly used evaluation of IBS. It includes 36 items, a total of 8 dimensions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable bowel syndrome quality of life (IBS-QOL) scale</measure>
    <time_frame>Baseline,1,and 3 month post randomization</time_frame>
    <description>Irritable bowel syndrome quality of life (IBS-QOL) scale is a more extensive application of the specific scale of IBS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionnaire</measure>
    <time_frame>1,and 3 month post randomization</time_frame>
    <description>To understand the patient's satisfaction with symptom control and diet guidance. The questionnaire included 3 items</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Food Habits</condition>
  <arm_group>
    <arm_group_label>Low FODMAPs Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instructed to low FODMAPs diet when patients signed the informed consent.
Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet Instruction</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low FODMAPs Diet</intervention_name>
    <description>Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet</description>
    <arm_group_label>Low FODMAPs Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet instruction</intervention_name>
    <description>Answer the doubt and help the patient get the diet knowlege about the IBS.</description>
    <arm_group_label>Low FODMAPs Diet</arm_group_label>
    <arm_group_label>Diet Instruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic criteria for Rome Ⅲ

          -  IBS patients with diarrhea type

          -  By endoscopy, X-ray, B ultrasound and laboratory examination to exclude organic
             disease

          -  Patients be able to communicate well with the researchers and be willing to
             participate in the study

        Exclusion Criteria:

          -  Stomach, small intestine, colon surgery history

          -  irritable bowel disease (IBD) active period, celiac disease

          -  Alcoholics or drug abuse

          -  Pregnant or lactating women

          -  Recent drug users who use defecation

          -  Have a special diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongcan Shi, Ph.D.,M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tianqi Zhou, Dr.</last_name>
    <phone>+8618852727248</phone>
    <email>651299080@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yamei Gu, Dr.</last_name>
    <phone>15252573426</phone>
    <email>286508374@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>YangzhouUniversity</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamei Gu, Dr.</last_name>
      <phone>+8615252573426</phone>
      <email>286508374@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Tianqi Zhou, Dr.</last_name>
      <phone>+8618852727248</phone>
      <email>651299080@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jinsong Wang, Ph.D.,M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.med.monash.edu.au/cecs/gastro/fodmap/iphone-app.html</url>
    <description>Monash University, D.o.G., The Monash University low FODMAP diet app. Melbourne Australia: Central Clinical School 2015 [updated 28 May 2015; cited 2015 4 June].</description>
  </link>
  <results_reference>
    <citation>Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023-34. doi: 10.1111/apt.12938. Epub 2014 Sep 9. Review.</citation>
    <PMID>25199904</PMID>
  </results_reference>
  <results_reference>
    <citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.</citation>
    <PMID>22426087</PMID>
  </results_reference>
  <results_reference>
    <citation>Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am. 2011 Mar;40(1):141-62. doi: 10.1016/j.gtc.2010.12.012. Review.</citation>
    <PMID>21333905</PMID>
  </results_reference>
  <results_reference>
    <citation>Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013 May;108(5):634-41. doi: 10.1038/ajg.2013.105.</citation>
    <PMID>23644955</PMID>
  </results_reference>
  <results_reference>
    <citation>Iacovou M, Tan V, Muir JG, Gibson PR. The Low FODMAP Diet and Its Application in East and Southeast Asia. J Neurogastroenterol Motil. 2015 Oct 1;21(4):459-70. doi: 10.5056/jnm15111.</citation>
    <PMID>26350937</PMID>
  </results_reference>
  <results_reference>
    <citation>De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. 2016 Jan;65(1):169-78. doi: 10.1136/gutjnl-2015-309757. Epub 2015 Jun 15. Review.</citation>
    <PMID>26078292</PMID>
  </results_reference>
  <results_reference>
    <citation>Gibson PR, Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology. 2015 May;148(6):1158-74.e4. doi: 10.1053/j.gastro.2015.02.005. Epub 2015 Feb 11. Review.</citation>
    <PMID>25680668</PMID>
  </results_reference>
  <results_reference>
    <citation>Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014 Jul 21;20(27):8859-66. doi: 10.3748/wjg.v20.i27.8859. Review.</citation>
    <PMID>25083059</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain I, Kumar V, Satyanarayana T. Xylooligosaccharides: an economical prebiotic from agroresidues and their health benefits. Indian J Exp Biol. 2015 Mar;53(3):131-42. Review.</citation>
    <PMID>25872243</PMID>
  </results_reference>
  <results_reference>
    <citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan;146(1):67-75.e5. doi: 10.1053/j.gastro.2013.09.046. Epub 2013 Sep 25.</citation>
    <PMID>24076059</PMID>
  </results_reference>
  <results_reference>
    <citation>Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015 Nov;149(6):1399-1407.e2. doi: 10.1053/j.gastro.2015.07.054. Epub 2015 Aug 5.</citation>
    <PMID>26255043</PMID>
  </results_reference>
  <results_reference>
    <citation>Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, Lomer MC. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet. 2015 Dec;28(6):687-96. doi: 10.1111/jhn.12318. Epub 2015 Apr 14.</citation>
    <PMID>25871564</PMID>
  </results_reference>
  <results_reference>
    <citation>Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016 Apr;55(3):897-906. doi: 10.1007/s00394-015-0922-1. Epub 2015 May 17. Review.</citation>
    <PMID>25982757</PMID>
  </results_reference>
  <results_reference>
    <citation>Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Aug;42(4):418-27. doi: 10.1111/apt.13286. Epub 2015 Jun 24.</citation>
    <PMID>26104013</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Jinsong Wang</investigator_full_name>
    <investigator_title>Director of Center for Clincal Epidemiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

